My SciELO
Custom servicesServices on Demand
Journal
Article
Spanish (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Cited by Google 
Similars in
SciELO 
Similars in Google
Share
Permalink
Farmacia Hospitalaria
On-line version ISSN 2171-8695Print version ISSN 1130-6343
Abstract
FERNANDEZ-CANABATE, Eva and FERNANDEZ-CANABATE, Sonia. Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin’s lymphoma. Farm Hosp. [online]. 2018, vol.42, n.1, pp.20-21. ISSN 2171-8695. https://dx.doi.org/10.7399/fh.10830.
Clinical case:
A 58-year-old woman with intraocular relapse of a diffuse large B cell lymphoma. Weekly intravitreal rituximab (1 mg/0.1 ml) for 4 weeks were administered. 12 months after the last intravitreal rituximab dose, signs and symptoms of lymphomas or adverse reactions associated with intravitreal Rituximab administration were not observed.
Discussion:
Intravitreal rituximab is an effective and safe treatment of intravitreal lymphoma, by inducing complete remission; it could be a good alternative to other therapeutic options with greater number of serious complications.
Keywords : Rituximab; Primary colon lymphoma; Diffuse large B cell lymphoma; Vitreoretinal lymphoma; Intravitreal injection; Non Hodgkin’s lymphoma.
